Management Team

Kenneth C. Carter, Ph.D.
President and CEO
Dr. Carter has been involved in the formation and early stage development of several biotechnology companies as a co-founder, consultant or member of the board of directors. He co-founded Avalon Pharmaceuticals, Inc. in January 1999 and served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. During this time, Avalon developed a unique biomarker-based drug discovery and development engine; completed an IPO and listing on the NASDAQ market; established a pipeline of drug discovery programs and partnerships with Merck, Novartis, Sanofi-Aventis, and AstraZeneca/MedImmune. Prior to that, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. Dr. Carter has served on the advisory and oversight boards for multiple biotechnology conferences and industry organizations including the National BIO Industry Organization and serves on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he holds an adjunct faculty appointment.

Scott Carmer 
Chief Operating Officer

Mr. Carmer brings 25 years of diverse leadership experience as a senior executive and chief commercialization officer in the biotech and pharmaceutical industry, with top-tier companies including AstraZeneca, MedImmune, Genentech, Amgen and GlaxoSmithKline. At AstraZeneca, he led the US Specialty Care Division of AstraZeneca with responsibility for the company’s portfolio of specialty care biopharmaceutical products. Prior to AstraZeneca, Mr. Carmer served as Executive Vice President, Commercial Operations of MedImmune. Mr. Carmer was also Vice President, Rheumatology Sales & Marketing for Genentech, where he was responsible for the US launches of Rituxan and ACTEMRA. Prior to Genentech, Mr. Carmer held several leadership roles of increasing responsibility at Amgen, most recently as Executive Director of Global Marketing. Mr. Carmer started his career at GlaxoSmithKline, where he held key roles in Global Brand Management, Business Development, Commercial Operations, Managed Care and Field Sales.

Alain Cappeluti, CPA
Chief Financial Officer
Mr. Cappeluti has over 30 years of experience in finance and public accounting for private and public companies, with more than 20 of those years spent in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. As the second employee of HGS in 1992 at the start of the human gene sequencing effort, he held positions of increasing responsibility and served for many years as Vice President of Finance. He has managed both large and small internal financial operations and has participated directly in approximately $4 billion of corporate financing transactions including private and public financings; IPOs; mergers and acquisitions; and real estate transactions. Mr. Cappeluti was part of the team that spun out CoGenesys from HGS in 2006 and was the CFO until the Company was sold to Teva Pharmaceuticals in 2008. Mr. Cappeluti is the President of Noble Life Sciences, serves on the board of O-Traces, Inc., an early stage cancer diagnostics Company, and is a consultant to other life science companies.